Trading Statement

2 Apr 2009 11:41



Omega Diagnostics Group Plc 

("Omega")

Trading Update

Omega, the AIM listed medical diagnostics company, announces that revenue for the year ended 31 March 2009 is £5.44m, some 56% ahead of last year's figure (31 March 2008: £3.49m). On a full like for like basis, turnover has increased by 20% combined, and individually across all three trading entities, where the figures in brackets for Genesis Diagnostics and Cambridge Nutritional Sciences represent the full 12-month comparative:

ODL has seen growth in most of its regions around the world, particularly in Africa/Middle East and Asian regions. Genesis has seen growth fuelled mainly by the roll-out into a number of territories of its microarray-based Genarrayt™ assay system for food intolerance, where evaluations are on-going which are expected to lead to increased sales of reagent kits going forward. CNS has benefited from launching the Food Detective™ kit into a number of European territories and from an increase in sales from its Foodprint™ laboratory testing service.

Profit before tax (and before share based payments, exceptional costs and amortisation of intangible assets) is expected to be in line with market expectations. 

The outlook for the new financial year is encouraging as we expect to continue to widen the roll-out of the Genarrayt™ system and to launch Food Detective™ into other new markets and we look forward to providing an update on progress when the full year results are announced in early July 2009.

Further enquiries: